DutchNews.nl - DutchNews.nl brings daily news from The Netherlands in English

2 October 2025
Newsletter Donate Advertise
  • News
  • Life in the Netherlands
  • Jobs
  • Podcast
  • About us
  • Search
  • Home
  • Economy
  • Election 2025
  • Art and culture
  • Sport
  • Europe
  • Society
  • Environment
  • Health
  • Housing
  • Education
  • News
    • Home
    • Economy
    • Election 2025
    • Art and culture
    • Sport
    • Europe
    • Society
    • Environment
    • Health
    • Housing
    • Education
  • Life in the Netherlands
    • Latest
    • Opinion
    • Books
    • Travel
    • 10 Questions
    • Learning Dutch
    • Inburgering with DN
    • Food & Drink
    • Ask us anything
  • Jobs
  • Podcast
  • About us
    • Team
    • Donate
    • Advertise
    • Writing for Dutch News
    • Contact us
    • Privacy
    • Newsletter
  • Search

Breakthrough Dutch cancer treatment held back by drug firms: FD

September 12, 2025
Photo: RadboudUMC

Dutch oncologists have developed pioneering immunotherapy treatments that cure more cancer patients with fewer drugs, but the methods remain out of reach for most patients because of opposition from the pharmaceutical industry, the Financieele Dagblad reported on Friday.

Doctors at the Antoni van Leeuwenhoek (AvL) hospital in Amsterdam reversed the standard treatment order by giving immunotherapy before surgery rather than after.

Their studies showed that this approach eliminated tumours in nearly all patients with advanced bowel cancer, with many still cancer-free three years later. Similar trials for skin cancer also showed far higher cure rates with shorter courses of drugs.

“Good results are welcome, but the best thing you can achieve is to change standard care and help as many people as possible,” oncologist Myriam Chalabi told the FD. Her team’s method requires only four weeks of immunotherapy, compared with up to a year under current protocols, reducing side effects and costs for patients.

But making the treatment widely available requires regulatory approval from the European Medicines Agency (EMA). Only the drugmaker that holds the licence can submit an application, and in this case that is US firm Bristol Myers Squibb (BMS).

The company has so far refused to file, a stance doctors attribute to financial concerns because shorter treatments mean selling fewer medicines, the FD said.

Oncologist Christian Blank faced similar resistance with his melanoma study, which showed that half of patients could skip further treatment after surgery.

His results were published in the New England Journal of Medicine and presented at a major oncology congress in Chicago. BMS initially backed his research but then pulled back, he said.

After years of pressure, BMS recently told the FD it is now “preparing” an application for authorisation, though it gave no timeline. In the meantime, Dutch doctors secured approval through the national health institute to offer the treatment nationally.

“We have treatments that are better and also cheaper, yet we cannot get them to our patients if the industry does not cooperate,” said AvL oncologist Gabe Sonke. The hospital is exploring producing its own versions of the drugs once patents expire to bypass what it calls market failure in bringing effective therapies to patients.

Share this article
  • Facebook
  • Twitter
  • LinkedIn
  • Reddit
  • Copy URL
Business Cancer Health Healthcare Research
Thank you for donating to DutchNews.nl.

We could not provide the Dutch News service, and keep it free of charge, without the generous support of our readers. Your donations allow us to report on issues you tell us matter, and provide you with a summary of the most important Dutch news each day.

Make a donation
Latest
Show more
Dutch will fetch seriously ill children from Gaza after all
Dutch tax office moves email to Microsoft despite privacy fears
Dutch "gradually" introduce new EU border system from October 12
The Dutch general election: how would you vote if you could?
Chatbots can't replace human customer service staff: regulators
NewsHomeEconomyElection 2025Art and cultureSportEuropeSocietyEnvironmentHealthHousingEducation
Life in the NetherlandsLatestOpinionBooksTravel10 QuestionsLearning DutchInburgering with DNFood & DrinkAsk us anything
About usTeamDonateAdvertiseWriting for Dutch NewsContact usPrivacyNewsletter
© 2025 DutchNews | Cookie settings

Help us to keep providing you information about coronavirus in the Netherlands.

Many thanks to everyone who has donated to DutchNews.nl in recent days!

We could not provide this service without you. If you have not yet made a contribution, you can do so here.

The DutchNews.nl team

Donate now

Dutchnews Survey

Please help us making DutchNews.nl a better read by taking part in a short survey.

Take part now